Articles related to LUNG CANCER

New research questions the life-extending efficacy of most common cancer screenings, emphasizing the need for transparent physician-patient discussions to weigh the risks and benefits. Learn more about this crucial topic that might change your approach to recommending screenings.

Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.

This phase 2 trial demonstrates the potential of perioperative nivolumab combined with chemotherapy in achieving higher pathological complete response and survival rates in stage III NSCLC. Explore the detailed findings to understand how this approach may influence future treatment paradigms.

The updated ASCO guidelines for stage IV NSCLC provide new treatment recommendations based on the latest evidence. Explore these changes and their potential impact on patient care.

The KEYNOTE-789 study results have sparked a debate on the role of immunotherapy in treating stage IV EGFR-mutated NSCLC. While the study did not show a significant benefit of adding pembrolizumab to chemotherapy, experts agree that the potential role of immunotherapy, particularly in combination with anti-angiogenic therapy, should not be completely dismissed.

Dr. Janet L. Espirito’s groundbreaking research demonstrates how real-world data can effectively be used to evaluate therapeutic responses in patients with mNSCLC. Discover how this innovative approach could shape the future of oncology treatment evaluation.